Aspire Therapeutics

Aspire Health Science is a clinical-stage biotechnology company focused on the development and manufacturing of innovative cell-based therapies. The company's lead program, AHB-001, is an autologous cell therapy being investigated for the treatment of critical limb ischemia (CLI), a severe form of peripheral artery disease. In addition to its internal pipeline, Aspire operates a state-of-the-art manufacturing facility in Orlando, Florida, providing contract development and manufacturing organization (CDMO) services for cell and gene therapy products. The company was acquired by Aeterna Zentaris in 2021 to bolster its pipeline and manufacturing capabilities in the regenerative medicine space.